11 completed, 2 terminated, 1 withdrawn. 6 Phase 2, 5 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 2 |
| Phase 3 | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 4 | Completed 4 |
Follow AK002: new trials by email Literature Review of AK002 trials Research Report on AK002
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria Lirentelimab (AK002), Placebo - Chronic Spontaneous Urticaria | Phase 2 | Terminated | Allakos Inc. | 127 | 2022-10-26 | 2024-09-27 |
| A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis AK002, Placebo - Atopic Dermatitis | Phase 2 | Terminated | Allakos Inc. | 131 | 2022-06-27 | 2024-10-15 |
| A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Withdrawn | Allakos Inc. | 2021-12-01 | 2023-03-03 | |
| A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis AK002, Placebo - Eosinophilic Duodenitis, Eosinophilic Gastroenteritis | Phase 3 | Completed | Allakos Inc. | 94 | 2021-05-20 | 2024-01-02 |
| An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) lirentelimab - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Completed | Allakos Inc. | 159 | 2020-12-03 | 2024-04-22 |
| A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis Placebo, lirentelimab (AK002) - Eosinophilic Esophagitis | Phase 2 / Phase 3 | Completed | Allakos Inc. | 277 | 2020-07-06 | 2024-01-02 |
| A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) lirentelimab (AK002), Placebo - Eosinophilic Gastritis, Eosinophilic Duodenitis | Phase 3 | Completed | Allakos Inc. | 181 | 2020-06-18 | 2024-01-02 |
| A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers lirentelimab (AK002), Placebo - Study Conducted in Healthy Volunteers | Phase 1 | Completed | Allakos Inc. | 66 | 2020-03-23 | 2023-04-18 |
| An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis AK002 - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Completed | Allakos Inc. | 58 | 2018-11-14 | 2024-02-28 |
| A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis AK002, Placebo - Eosinophilic Gastritis, Eosinophilic Gastroenteritis | Phase 2 | Completed | Allakos Inc. | 65 | 2018-07-18 | 2024-01-19 |
| A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis AK002 - Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis | Phase 1 | Completed | Allakos Inc. | 30 | 2018-02-26 | 2019-08-29 |
| A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria AK002 - Chronic Urticaria | Phase 2 | Completed | Allakos Inc. | 47 | 2018-01-23 | 2024-03-04 |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants AK002, Placebo - Healthy | Phase 1 | Completed | Allakos Inc. | 51 | 2016-08-01 | 2017-09-26 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 AK002 - Indolent Systemic Mastocytosis | Phase 1 | Completed | Allakos Inc. | 25 | 2016-06-01 | 2019-03-13 |
Eosinophilic Esophagitis (6) · Eosinophilic enteropathy (6) · Chronic Urticaria (2) · Conjunctivitis, Allergic (1) · Dermatitis (1) · Dermatitis, Atopic (1) · Eczema (1) · Esophagitis (1) · Mastocytosis (1) · Mastocytosis, Systemic (1) · Urticaria (1)
Allakos Inc. (14)
United States (12) · Germany (4) · Australia (2) · Netherlands (1) · Poland (1)
Craig Paterson, MD (5) · Henrik Rasmussen, MD, PhD (3) · Chin Lee, MD, MPH (2) · Craig Patterson, MD (1) · Jason Lickliter, MBBS PhD (1) · Marcus Maurer, MD (1) · Quan D Nguyen, MD, MSc (1)